Cleaning validation is a process that demonstrates the consistency and effectiveness of cleaning pharmaceutical production equipment. Validation detects and analyses the optimization potential and supports the implementation. Pharmaceutical manufacturers often create many product types in one facility. Often, different strengths are prepared for the same product. Cleaning processes and types of products can present a significant challenge for facilities given the multitude of procedures and equipment types involved. The variety of cleaning methods, assays, and equipment to be checked can be overwhelming 1.

Compliance with current good manufacturing practice (cGMP) regulations is crucial for ensuring quality of the product, with cleaning being a critical factor. In virtually all aspects of manufacturing, cleaning is a crucial process that extends from the initial bulk-production stage to the final form of dosage. The risk posed by cross-contamination is considered significant by the FDA and poses a serious threat to public health. The Food and Drug Administration (FDA) mandates that companies possess written guidelines known as standard operating procedures (SOPs) that outline the cleaning methods utilized for a range of equipment 2.

Amoxicillin is a type of antibiotic known as a semi-synthetic penicillin (β-lactam antibiotic), which is often combined with the beta-lactamase inhibitor potassium clavulanate (the potassium salt of clavulanic acid) to create a broad-spectrum agent that effectively targets a range of bacterial pathogens commonly found in general practice and hospitals. It prevents the formation of cross-links between linear peptidoglycan polymer chains, which are a significant component of the cell walls of both Gram-positive and Gram-negative bacteria 3, 4. Analytical techniques for potassium clavulanate and amoxicillin mixtures have been documented in USP and BP for both tablets and oral suspensions 5, whereas injections have only been reported for BP 6. Potassium clavulanate and amoxicillin quantification in these medication formulations has been detailed in the pharmacopoeia. However, no related substance methods have been described for the determination of impurities in USP for both oral suspensions and tablets, where potassium clavulanate and amoxicillin were present in the mixtures. In BP, methods for co-amoxiclav drug formulations (oral suspension and tablets) were described using only the amount of amoxicillin dimer impurity (amox-imp J), which was determined by its relative retention time to amoxicillin. A different related substance approach was presented in the British Pharmacopoeia (BP) for co-amoxiclav injections, which involved the use of an amoxicillin impurity standard comprising penicilloic acid (amox-imp D) and amoxicillin dimer (amox-imp J) impurities6.

Cloxacillin is a semi-synthetic antibiotic belonging to the class same as that of penicillin, and it is utilized for combating staphylococci that generate β-lactamase. This drug has less potent antibacterial properties compared to benzylpenicillin, and does not cause any significant toxicity, with the exception of allergic reactions. It is utilized to combat staphylococci that generate β-lactamases. From a literature survey, it was found that several procedures have been tested for both drugs individually, but no HPLC techniques have been reported for such a combination in any type of pharmaceutical dosage form thus far 6. The present work depicts a precise, simple, and accurate reverse-phase HPLC approach for the simultaneous amoxycillin and cloxacillin estimation in combination with the dosage form7.

Cleaning was the starting step of the manufacturing process. Validation is a process that involves providing evidence that is both documented and consistent, thereby ensuring that reproducible outcomes can be achieved. Cleaning validation shows that the cleansing process consistently produces residue levels that are well below the scientifically established acceptance criteria, which provide a higher degree of assurance in the effectiveness of the process. A comprehensively designed and rigorously tested cleaning process guarantees the eradication of contamination risks, thereby preserving patient security and ensuring product quality. Cleaning process validation is one of the long-standing Good Manufacturing Practice mandated by global regulatory authorities, and widely implemented by the pharmaceutical industry. The importance of cleaning validation has increased significantly because of the expansion and growth of multiproduct manufacturing facilities that use shared equipment for manufacturing.

In recent times, cleaning validation has emerged as a highly debated and evolving topic, raising a number of concerns and queries pertaining to various practices. The aim of this research is to offer recommendations for the best approaches related to cleaning validation based on the principles outlined in a range of global regulatory guidelines, including the practices that are commonly employed by leading Indian pharmaceutical companies 8. The aim of this study was to verify the effectiveness of cleaning equipment used in manufacturing units by checking the residue level and to determine whether cleaning can limit the residue to a predetermined acceptance level for a continuous process.

The main aim of this work is to present conclusive evidence that the cleaning techniques utilized in a facility consistently keep the carryover of products, which also includes impurities and intermediates, as well as cleaning agents, and extraneous material into subsequent products to a level that falls below predetermined limits. In addition, there was no possibility of cross-contamination.

Broadly, this research endeavored to select a drug using a cross-matrix approach, and Cloxacillin Sodium was selected using this approach. Thus, the HPLC method for Cloxacillin Sodium was validated. A recovery study was conducted using a swab sampling method on a stainless-steel vessel, and the procedure was validated for cleaning the equipment used in manufacturing. The collected samples were analysed for chemical (swab and rinse) and microbial contamination, and the acceptance limit for drug carryover to the next batch was checked.

Cleaning validation studies were carried out at the parental department on the product change between Cloxacillin Sodium and Amoxicillin Potassium Clavulanate. The analytical method for Cloxacillin Sodium was validated by HPLC. The HPLC spectra of the standard and sample solutions were recorded. The Accuracy of this method was determined using recovery studies. Recovery studies were performed, and the percentage recovery was calculated. The proposed method was found to be satisfactory in terms of its results, as demonstrated by the effectiveness of both cloxacillin and ampicillin. Ruggedness and Robustness were determined, and the % RSD values calculated from precision studies were less than + 2.0 results obtained were subjected to statistical analysis to determine standard deviation values. All validation parameters were within the limits.

The proposed High Performance Liquid Chromatography (HPLC) technique was simple and rapid. Hence, this procedure is appropriate for testing the quality of the raw materials and finished products. Recovery studies were performed on stainless-steel vessels using the swab technique. The amount recovered using the swab technique was > 70%. Therefore, the recovery study performed seemed to be suitable for the swabbing procedure followed for sample collection in cleaning validation studies of Cloxacillin Sodium. The outcome of the cleaning procedure used for chemical analysis was within the acceptance criteria (Table 1).

Cleaning validation for the equipment utilized in the manufacturing process was carried out for the last batch of Cloxacillin Sodium. (cloxacillin) to provide documented evidence ensuring that cleaning, as per the Standard Operating Procedure, yields concurrent and consistent results, which are well within the acceptance criteria. Cleaning validation for the manufacture of Cloxacillin Sodium was conducted for the last batch to ensure compliance with the Standard Operating Procedure. The collection of samples was done using swab and rinse methods, revealing a residual carryover of 5.6868 mg/swab (swab method) and 28.14 mg/rinse (rinse method) (Table 2 and Table 3).

Microbial swab analysis was also carried out to determine the growth of bacteria and fungi. The maximum total viable count for the last batch of Cloxacillin Sodium was noted to be 0cfu/swab. The outcomes met the specified acceptance criteria of 10 ppm and a MACO limit of 420 mg for chemical analysis and 1 cfu/swab for microbial analysis. With satisfactory completion of the cleaning validation, it was determined that the cleaning process followed was appropriate and could limit the drug residue to an intended level according to the company requirements.

The developed analytical method for Cloxacillin Sodium was validated and found to fall within the intended specifications. The acceptable limits for swab and rinse values were within MACO standards. The maximum total viable count for the last batch of 500 mg of Cloxacillin Sodium was found to be 0 cfu, which was well within the acceptance limit of 1 cfu/swab. All the chemical and microbiological results met the acceptance criteria. Hence, the cleaning procedure utilized for the entire equipment chain was satisfactory.